DDI Drug Name |
DDI Drug ID |
Severity |
Mechanism |
Comorbidity |
REF |
Bedaquiline |
DM3906J
|
Major |
Increased risk of prolong QT interval by the combination of Lopinavir and Bedaquiline. |
Antimicrobial drug resistance [MG50-MG52]
|
[18] |
Levalbuterol |
DM5YBO1
|
Moderate |
Increased risk of prolong QT interval by the combination of Lopinavir and Levalbuterol. |
Asthma [CA23]
|
[19] |
Retigabine |
DMGNYIH
|
Moderate |
Increased risk of prolong QT interval by the combination of Lopinavir and Retigabine. |
Behcet disease [4A62]
|
[17] |
Eribulin |
DM1DX4Q
|
Moderate |
Increased risk of prolong QT interval by the combination of Lopinavir and Eribulin. |
Breast cancer [2C60-2C6Y]
|
[17] |
Olodaterol |
DM62B78
|
Moderate |
Increased risk of prolong QT interval by the combination of Lopinavir and Olodaterol. |
Chronic obstructive pulmonary disease [CA22]
|
[19] |
Indacaterol |
DMQJHR7
|
Moderate |
Increased risk of ventricular arrhythmias by the combination of Lopinavir and Indacaterol. |
Chronic obstructive pulmonary disease [CA22]
|
[19] |
Pasireotide |
DMHM7JS
|
Major |
Increased risk of prolong QT interval by the combination of Lopinavir and Pasireotide. |
Cushing syndrome [5A70]
|
[20] |
Tetrabenazine |
DMYWQ0O
|
Moderate |
Increased risk of prolong QT interval by the combination of Lopinavir and Tetrabenazine. |
Dissociative neurological symptom disorder [6B60]
|
[17] |
Deutetrabenazine |
DMUPFLI
|
Moderate |
Increased risk of prolong QT interval by the combination of Lopinavir and Deutetrabenazine. |
Dystonic disorder [8A02]
|
[17] |
Polyethylene glycol |
DM4I1JP
|
Moderate |
Increased risk of ventricular arrhythmias by the combination of Lopinavir and Polyethylene glycol. |
Irritable bowel syndrome [DD91]
|
[21] |
Phenolphthalein |
DM5SICT
|
Moderate |
Increased risk of ventricular arrhythmias by the combination of Lopinavir and Phenolphthalein. |
Irritable bowel syndrome [DD91]
|
[20] |
Hydroxychloroquine |
DMSIVND
|
Major |
Increased risk of prolong QT interval by the combination of Lopinavir and Hydroxychloroquine. |
Malaria [1F40-1F45]
|
[22] |
Inotuzumab ozogamicin |
DMAC130
|
Moderate |
Increased risk of prolong QT interval by the combination of Lopinavir and Inotuzumab ozogamicin. |
Malignant haematopoietic neoplasm [2B33]
|
[17] |
Vemurafenib |
DM62UG5
|
Major |
Increased risk of prolong QT interval by the combination of Lopinavir and Vemurafenib. |
Melanoma [2C30]
|
[17] |
Fingolimod |
DM5JVAN
|
Major |
Increased risk of ventricular arrhythmias by the combination of Lopinavir and Fingolimod. |
Multiple sclerosis [8A40]
|
[17] |
Lofexidine |
DM1WXA6
|
Moderate |
Increased risk of prolong QT interval by the combination of Lopinavir and Lofexidine. |
Opioid use disorder [6C43]
|
[17] |
Triclabendazole |
DMPWGBR
|
Moderate |
Increased risk of prolong QT interval by the combination of Lopinavir and Triclabendazole. |
Parasitic worm infestation [1F90]
|
[17] |
Macimorelin |
DMQYJIR
|
Major |
Increased risk of prolong QT interval by the combination of Lopinavir and Macimorelin. |
Pituitary gland disorder [5A60-5A61]
|
[23] |
Degarelix |
DM3O8QY
|
Moderate |
Increased risk of prolong QT interval by the combination of Lopinavir and Degarelix. |
Prostate cancer [2C82]
|
[21] |
ABIRATERONE |
DM8V75C
|
Moderate |
Increased risk of prolong QT interval by the combination of Lopinavir and ABIRATERONE. |
Prostate cancer [2C82]
|
[21] |
Selexipag |
DMAHSU0
|
Minor |
Decreased metabolism of Lopinavir caused by Selexipag mediated inhibition of CYP450 enzyme. |
Pulmonary hypertension [BB01]
|
[24] |
Amisulpride |
DMSJVAM
|
Major |
Increased risk of prolong QT interval by the combination of Lopinavir and Amisulpride. |
Schizophrenia [6A20]
|
[25] |
Asenapine |
DMSQZE2
|
Moderate |
Increased risk of prolong QT interval by the combination of Lopinavir and Asenapine. |
Schizophrenia [6A20]
|
[17] |
Armodafinil |
DMGB035
|
Moderate |
Increased metabolism of Lopinavir caused by Armodafinil mediated induction of CYP450 enzyme. |
Solid tumour/cancer [2A00-2F9Z]
|
[26] |
Vandetanib |
DMRICNP
|
Major |
Increased risk of prolong QT interval by the combination of Lopinavir and Vandetanib. |
Solid tumour/cancer [2A00-2F9Z]
|
[20] |
Triptorelin |
DMTK4LS
|
Moderate |
Increased risk of prolong QT interval by the combination of Lopinavir and Triptorelin. |
Solid tumour/cancer [2A00-2F9Z]
|
[21] |
Pitolisant |
DM8RFNJ
|
Moderate |
Increased risk of prolong QT interval by the combination of Lopinavir and Pitolisant. |
Somnolence [MG42]
|
[17] |
Telavancin |
DM58VQX
|
Moderate |
Increased risk of prolong QT interval by the combination of Lopinavir and Telavancin. |
Staphylococcal/streptococcal disease [1B5Y]
|
[17] |
Lenvatinib |
DMB1IU4
|
Moderate |
Increased risk of prolong QT interval by the combination of Lopinavir and Lenvatinib. |
Thyroid cancer [2D10]
|
[17] |
----------- |
|
|
|
|
|